Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Limertinib is a high-purity, irreversible small-molecule inhibitor that selectively targets mutant EGFR in vitro. Designed specifically for laboratory research, it is ideal for investigating signal transduction, kinase activity, and receptor molecular mechanisms in cell-free or in vitro systems. This compound is suitable for mechanistic studies, target validation, and enzymatic assays.

Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) at 80 mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M‑mutated non‑small cell lung cancer, including patients with brain metastases.⚠️ For research use only – Not for human consumption or therapeutic use.

Innovent Biologics announces NMPA approval for Limertinib, a pioneering treatment for lung cancer, marking a significant advancement in patient care.

SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and...

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of…